Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05604560 · ClinicalTrials.gov registry record · Phase 2
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
A Phase 2 study of Pancreatic Cancer, sponsored by Lei Zheng.
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT05604560 is a Phase 2 study of Pancreatic Cancer that is active but no longer recruiting, run by Lei Zheng. The registered enrollment target is 25 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05604560, a Phase 2 study of Pancreatic Cancer, is active but no longer recruiting, sponsored by Lei Zheng.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and clinical activity of tislelizumab (an anti-PD-1 antibody) in combination with SX-682 (a CXCR1/2 inhibitor) in subjects with newly diagnosed and surgically resectable pancreatic adenocarcinoma.
Conditions Studied
Interventions
- DRUG Tislelizumab
- DRUG SX-682
Study Locations (2)
Maryland
- Johns Hopkins SKCCC - Baltimore
Texas
- The University of Texas Health Science Center San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-11-08 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05604560
The ClinicalTrials.gov registry entry for NCT05604560 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Lei Zheng, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Tislelizumab is the first listed.
NCT05604560 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Texas.
Frequently Asked Questions
What is clinical trial NCT05604560 about?
NCT05604560 is a clinical study titled "A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer". The purpose of this study is to evaluate the safety and clinical activity of tislelizumab (an anti-PD-1 antibody) in combination with SX-682 (a CXCR1/2 inhibitor) in subjects with newly diagnosed and surgically resectable pancreatic adenocarcinoma.
What is the current status of trial NCT05604560?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2023-11-08. Estimated completion is 2026-09.
What conditions does trial NCT05604560 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT05604560?
The interventions under investigation include: Tislelizumab (DRUG), SX-682 (DRUG).
Who is sponsoring clinical trial NCT05604560?
This trial is sponsored by Lei Zheng, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05604560 being conducted?
This trial has 2 study locations across Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.